FDA shares additional draft guidance on CGTs
The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.
Corporate Governance
Trump 2.0 spells uncertainty for US healthcare, says analyst
Reeves’ 2024 budget promises life sciences investment
mRNA licensing agreements surge 800% amid GSK lawsuits
As mpox spreads, ‘national governments have a moral responsibility to help’
What is mpox and how big of a threat is it?
Why COP28 is “the most important COP” since the Paris Agreement
Why COP28 is “the most important COP” since the Paris Agreement
